(Q84668296)
Statements
Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer (English)
Benedito A Carneiro
Ramesh K Ramanathan
Marwan G Fakih
Smitha S Krishnamurthi
Barry C Lembersky
Ronald G Stoller
Stewart L Lancaster
Richard A Pinkerton
Theodore L Crandall
Amy R Schmotzer
Douglas M Potter